Perioperative Versus Postoperative CapOX Chemotherapy for Locally Advanced Colon Cancer

NCT03125980 | Recruiting Phase 3

• 1 other identifier: CapeOXcc
• Study Type: interventional
• Target: 1,370
• Locations: 1 country
• Sites: 1

Brief Summary

Adjuvant chemotherapy has been widely adopted worldwide for locally advanced colon cancer. However, more and more studies have found better efficacy and potential advantages of perioperative or neoadjuvant chemotherapy. The sooner the systemic chemotherapy is received, the better suppression it has on activity of tumor growth factors. Pre-operative chemotherapy may eliminate tiny metastases. It may also shrink the invasion of tumor before surgery, and thus reducing operational trauma and expediting recovery. With advances in radiology and tomography, staging before surgery is accurate enough to identify risks and prognosis for patients. The phase II trial conducted by our department has yielded encouraging results (N=47, CapeOX regimen, clinicaltrials.gov NCT02415829): after the neoadjuvant chemotherapy, no subject had disease progression, 68.1% subjects reached complete or partial response. Besides, the toxicity of neoadjuvant CapeOX chemotherapy was acceptable. The present randomized controlled phase III trial will be conducted to further compare efficacy and safety of the neoadjuvant and adjuvant CapeOX chemotherapy for patients with locally advanced resectable colon cancer in China. This study may have two periods, each will last for approximately 5 years. After the first period (n=994), if the results of the test group are better than the control group, the study will be terminated. Otherwise, the study will enter into period 2 (n=376) through selecting out genetically sensitive subjects and repeating the same trial process as period 1.

Conditions

Locally Advanced Colon Cancer

Outcome Measures

Primary Outcomes (1)

• 3-year disease free survival

  Defined as the length of time from the date of randomization until the first documented date of progression or death from any cause, whichever comes first

  3 years

Secondary Outcomes (4)

• R0 resection rate

  From the date of randomization until the date of the last patient receiving surgery, assessed up to 40 months

• Post-operative TRG staging

  From the date of randomization until the date of the last patients receiving surgery, assessed up to 40 months

• Overall survival (OS)

  5 years

• Relapse-free survival (RFS)

  5 years

Study Arms (2)

Perioperative chemotherapy with CapOX regimen

EXPERIMENTAL

Drug: capecitabine plus oxaliplatin before and after surgery

Postoperative chemotherapy with CapOX regimen

ACTIVE COMPARATOR

Drug: capecitabine plus oxaliplatin after surgery

Interventions

capecitabine plus oxaliplatin before and after surgery DRUG

Subjects will receive systemic CapeOX chemotherapy both before and after the radical surgery for at most 4 cycles respectively. They shall have rest after the surgery for at least four weeks before the post-operative chemotherapy. CapOX regimen will be administered as follows: 1. Oxaliplatin 130 mg/m2 iv continue for 2 hours.D1 2. Capecitabine 1000mg/m2/d PO Bid,once every morning and evening D1-14 3. Repeat every 3 weeks (Q3W)

Perioperative chemotherapy with CapOX regimen

capecitabine plus oxaliplatin after surgery DRUG

Subjects will first receive radical surgery, then have rest for at least four weeks. Thereafter, subjects will receive systemic CapeOX chemotherapy for at most 8 cycles. CapOX regimen will be administered as follows: 1. Oxaliplatin 130 mg/m2 iv continue for 2 hours.D1 2. Capecitabine 1000mg/m2/d PO Bid,once every morning and evening D1-14 3. Q3W

Postoperative chemotherapy with CapOX regimen

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 2;
• Adequate bone marrow, hepatic and renal function as assessed by the following laboratory requirements conducted within 7 days of starting study treatment: Neutrophil count≥1.5×109/L, Platelet count≥100×109/L, Hemoglobin≥80g/L, Serum bilirubin≤24umol/L, Alanine aminotransferase and aspartate aminotransferase ≤ 60×IU/L, Serum creatinine≤110 umol/L;
• No current pregnancy or breast-feeding, and subjects at childbearing age shall take method of contraception ;
• Be in a condition to receive a surgery/procedure;
• No second tumor at present or in the past 5 years, except skin basal cell carcinoma, skin squamous cell carcinoma, or any in situ cancer;
• No previous systemic chemotherapy for treating colon cancer;
• No other chemotherapy at the same time;
• Expected lifetime longer than three months;
• Be willing and able to understand the study and to provide written informed consent.

You may not qualify if:

• End-stage cachexia patients;
• Cardiopulmonary dysfunction or liver and kidney dysfunction, and unable to tolerate CapeOX chemotherapy;
• Metastatic carcinoma;
• Moderate or above anemia caused by serious local tumor bleeding;
• Incomplete or complete intestinal obstruction;
• Known to be allergic to oxaliplatin or capecitabine;
• Active hepatitis, severe coagulation disorder patients;
• Pregnant or lactating women; or women who have fertility but have not taken at taken adequate contraceptive measures;
• Known to have deficient dihydropyrimidine dehydrogenase (DPD)；
• Have vital organ failure or other severe diseases, including but not limited to coronary heart disease, cardiovascular diseases, or myocardial infarction within 12 months before being included; severe neurological or psychiatric history；severe infection; active disseminated intravascular coagulation;
• Unable or unwilling to abide by the study plan.

Sponsors & Collaborators

• Fudan University: lead

Study Sites (1)

Department of Colorectal Surgery Fudan University Shanghai Cancer Center

Shanghai, Shanghai Municipality, 200032, China

RECRUITING

Related Publications (1)

• Liu F, Tong T, Huang D, Yuan W, Li D, Lin J, Cai S, Xu Y, Chen W, Sun Y, Zhuang J. CapeOX perioperative chemotherapy versus postoperative chemotherapy for locally advanced resectable colon cancer: protocol for a two-period randomised controlled phase III trial. BMJ Open. 2019 Jan 29;9(1):e017637. doi: 10.1136/bmjopen-2017-017637.

  PMID: 30700474 DERIVED

MeSH Terms

Interventions

Capecitabine; Postoperative Period

Intervention Hierarchy (Ancestors)

Deoxycytidine; Cytidine; Pyrimidine Nucleosides; Pyrimidines; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Fluorouracil; Uracil; Pyrimidinones; Deoxyribonucleosides; Nucleosides; Nucleic Acids, Nucleotides, and Nucleosides; Perioperative Period; Surgical Procedures, Operative; Patient Care; Health Services; Health Care Facilities Workforce and Services

Study Officials

• Ye Xu, M.D

  Department of Colorectal Surgery Fudan University Shanghai Cancer Center

  STUDY DIRECTOR

Central Study Contacts

Sanjun Cai, M.D

CONTACT

+86-21-64175590; caisanjuncsj@163.com

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: NONE
• Masking Details: Open label
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor, Chief physician

Study Record Dates

• First Submitted: April 14, 2017
• First Posted: April 24, 2017
• Study Start: May 1, 2017
• Primary Completion: May 1, 2022
• Study Completion (Estimated): May 1, 2027
• Last Updated: April 24, 2017

Record last verified: 2017-04

Locations

CN (1)